Drug intelligence / Profile preview

RO-14

Development stage: Phase 1
Lead developer: Rovi
Modality: Small Molecules
Administration: Subcutaneous

Overview

RO-14 is an investigational ultra low molecular weight heparin developed as a small molecule drug for subcutaneous administration. Its primary mechanism of action is inhibition of factor Xa, making it part of the class of factor Xa inhibitors. The drug has been studied in Phase 1 clinical trials to evaluate its tolerability and pharmacokinetics in healthy male volunteers, with potential indications in cardiovascular diseases such as thromboembolism, thrombosis, and venous thrombosis. The originator and main developer is Laboratorios Farmaceúticos Rovi SA[1].

Targets

F10 (Factor Xa)

Beyond the preview

Go deeper on RO-14.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RO-14.

Explore the full profile